Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $124.7 million SEC-registered offering of 28,503,220 shares of common stock and pre-funded warrants to purchase 1,914,280 shares of common stock by IVERIC bio, including the full exercise by the underwriters of their option to purchase 3,967,500 additional shares of common stock and as placement agents in connection with a $35.5 million concurrent private placement of 8,649,453 shares of common stock. IVERIC’s common stock is listed on the Nasdaq Global Select Market under the symbol “ISEE.”
Based in New York and New Jersey, IVERIC is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. IVERIC is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Roshni Banker Cariello, Richard Corbett, Johnathan M. Nixon, Dylan H. Lojac and Chelsea Renter. The tax team included counsel Ethan R. Goldman and associate Lex L. Varga. Associate Jay Frankel provided intellectual property advice. All members of the Davis Polk team are based in the New York office.